Curocell Inc. (KOSDAQ:372320)

South Korea flag South Korea · Delayed Price · Currency is KRW
55,600
+1,500 (2.77%)
At close: Apr 9, 2026
Market Cap846.70B +105.6%
Revenue (ttm)n/a
Net Income-46.31B
EPS-3,232.00
Shares Out15.04M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume133,113
Average Volume142,158
Open54,000
Previous Close54,100
Day's Range53,200 - 56,700
52-Week Range23,750 - 58,900
Beta1.19
RSI59.99
Earnings DateMar 27, 2026

About Curocell

Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals. It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors. The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T. Curocell Inc. was founded in 2016 and is headquartered in Daejeon, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 372320
Full Company Profile

Financial Performance

Financial Statements